Across the industry, more specialty therapies are competing for the same patients than ever before, and as clinical differences between them narrow, patient experience has become one of the few levers left for biopharma companies to stand out commercially. In this Dedicated Dialogue video interview, Courier Health Founder and CEO, Danny Sigurdson, joins Pharmaceutical Executive to unpack why so many companies claim to be patient-centric, but few actually deliver—and what it takes to close that gap. The conversation turns to AI adoption in biopharma, where Sigurdson shares findings from Courier Health's State of Patient-Centricity in Biopharma 2026 report , including that nearly 60% of biopharma companies consider their data fragmented or inactionable, and fewer than 10% have the data maturity to use AI in a meaningful way. He breaks down why access to AI tools doesn't equal adoption, and why the real bottleneck is tying data and technology into actual workflows—with alignment across business, IT, and security and compliance teams. He closes with an optimistic look at how AI, if built on the right foundation, can free teams to focus on the personalization, empathy, and engagement that matter most to patients.